| Gene symbol | DDIT4 | Synonyms | Dig2, REDD-1, REDD1 | Type of gene | protein-coding |
| Chromosome | 10 | Map location | 10q22.1 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | DNA damage inducible transcript 4 | ||||
| GTO ID | GTC1394 |
| Trial ID | NCT01445899 |
| Disease | Diabetic Macular Edema | Choroidal Neovascularization | Diabetic Retinopathy |
| Altered gene | DDIT4 |
| Therapeutic/Target gene | Target gene |
| Therapy | siRNA |
| Treatment | PF-04523655|REDD14NP|PF-655 |
| Phase | Phase2 |
| Recruitment status | Completed |
| Title | An Open-Label Dose Escalation Study of PF-04523655 (Stratum I) Combined With a Prospective, Randomized, Double-Masked, Multi-Center, Controlled Study (Stratum II) Evaluating the Efficacy and Safety of PF-04523655 Alone and in Combination With Ranibizumab Versus Ranibizumab Alone in Diabetic Macular Edema (MATISSE STUDY) |
| Year | 2012 |
| Country | Belgium|Czech Republic|Germany|Israel|Poland|United Kingdom|United States |
| Company sponsor | Quark Pharmaceuticals |
| Other ID(s) | QRK202|2011-004157-66 |
| Cohort1: PF-04523655_6 monthly injections | |||||||
|
|||||||
| Cohort2: ranibizumab_PF-04523655 | |||||||
|
|||||||
| Cohort3: ranibizumab | |||||||
|
|||||||
| Cohort4: PF-04523655_single injection | |||||||
|
|||||||